A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy.

Trial Profile

A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 04 Jul 2012 Planned number of patients changed from 689 to 906 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top